Download Hidradenitis suppurativa — From White Space to Benchmark Space Whitepaper

"In HS, the next therapy will not win because the pathway makes sense.
It will win because the product profile makes sense."

Why This Whitepaper Is a Must-Read

The competitive benchmark, mapped in full. A structured analysis of how adalimumab, secukinumab, bimekizumab, and povorcitinib have collectively raised the bar — and what that bar now demands from new entrants across efficacy depth, durability, safety tolerance, and line-of-therapy positioning.

KOL intelligence on what actually changes prescribing. Primary interviews with dermatology KOLs on the depth-of-response thresholds, safety expectations, dosing burden, and evidence standards that would genuinely shift practice. HiSCR50 is no longer the endpoint that earns clinical attention.

A decision framework for next-wave assets. The Proof of Position framework — five dimensions that determine whether an IRAK4, IL-1-axis, or oral immunology asset can earn a clinically meaningful, commercially defensible role in therapy — with a minimum-versus-differentiated bar mapped for each.

Strategic implications by audience. Distinct evidence agendas for pharma teams building benchmark-aware target product profiles, consultants advising on category positioning and evidence architecture, and investors evaluating signal quality, modality differentiation, and target versus asset risk.